Boston, Massachusetts, United States, November 9, 2026
HotSpot Therapeutics, Inc., a biotechnology company developing innovative oral medicines, has announced new preclinical data for HST-2011, an investigational small-molecule inhibitor of interferon regulatory factor 5 (IRF5). The findings were presented at the American College of Rheumatology (ACR) Convergence 2026, held in Orlando, Florida, from November 6–11, 2026. The research demonstrates the ability of HST-2011 to inhibit multiple immune pathways associated with systemic lupus erythematosus (SLE) and other autoimmune diseases. According to HotSpot, the candidate produced coordinated effects on abnormal B-cell activation, type I interferon signaling and proinflammatory cytokine production. These mechanisms play important roles in immune-system dysfunction and chronic inflammation. The findings support continued development of HST-2011 as a potential oral treatment for autoimmune disorders, although the candidate remains at the preclinical stage.
HST-2011 Targets Three Key Autoimmune Disease Pathways
The newly presented research examined how HST-2011 inhibits IRF5, a transcription factor involved in regulating innate and adaptive immune responses. IRF5 contributes to several inflammatory processes implicated in autoimmune diseases, particularly systemic lupus erythematosus. HotSpot reported that HST-2011 demonstrated inhibitory activity across three important disease-associated pathways: abnormal B-cell activation and autoantibody production, type I interferon signaling, and proinflammatory cytokine production. In human cellular systems, the investigational compound inhibited plasmablast formation and immunoglobulin G (IgG) production. Plasmablasts are antibody-producing cells that can contribute to abnormal immune activity in autoimmune disorders. The compound also reduced the production of type I interferons and inflammatory cytokines, including tumor necrosis factor (TNF) and interleukin-1 beta (IL-1β). These findings are significant because excessive activation of these pathways can contribute to persistent inflammation and tissue damage in patients with lupus. By targeting IRF5, HotSpot aims to influence several interconnected immune mechanisms through a single therapeutic approach. However, these observations were generated in experimental systems and do not establish clinical benefits in patients.
Preclinical Studies Demonstrate Coordinated Immune Effects
Additional experiments evaluated HST-2011 in human whole-blood samples stimulated with a toll-like receptor (TLR) agonist, an experimental approach used to activate immune signaling pathways. The company reported reductions in plasmablast, B-cell activation and interferon gene signature scores following treatment with HST-2011. Messenger RNA sequencing also demonstrated decreased expression of IFNB1, TNF and IL1B, genes associated with interferon activity and inflammatory cytokine production. These results provide molecular evidence supporting the compound’s effects on immune regulation. HotSpot also conducted preclinical studies involving cynomolgus monkeys to investigate whether oral administration could produce similar biological responses. Following oral dosing, ex vivo whole-blood analyses demonstrated reductions in plasmablast and interferon gene signature scores. Researchers also observed decreased expression of IFNB1, TNF and IL1B, consistent with findings from the human blood experiments. The agreement between the experimental systems supports the company’s proposed mechanism of action and provides a rationale for further development. Nevertheless, the findings remain preclinical, and additional studies are needed to evaluate appropriate dosing, safety, pharmacokinetics and therapeutic effectiveness in humans.
Advertisement
Smart Allostery Platform Supports Future Drug Development
HST-2011 is an investigational, non-covalent, non-degrading allosteric small-molecule inhibitor of IRF5. Unlike traditional drug-discovery approaches that target conventional active sites, allosteric inhibitors interact with alternative regulatory regions of proteins to modify their activity. IRF5 has historically been considered challenging to target because it lacks a conventional active site suitable for many small-molecule medicines. HotSpot developed HST-2011 using its proprietary Smart Allostery™ platform, which combines computational research, artificial intelligence-driven data analysis, specialized pharmacology and medicinal chemistry. The platform identifies naturally occurring regulatory pockets, described as natural hotspots, that control protein function. Genetic research has linked IRF5 to several immune-mediated conditions, including systemic lupus erythematosus, cutaneous lupus erythematosus, Sjögren’s disease, rheumatoid arthritis, systemic sclerosis and myositis. Geraldine Harriman, PhD, Co-Founder and Chief Scientific Officer of HotSpot Therapeutics, highlighted the potential of IRF5 inhibition to influence multiple immune pathways implicated in autoimmune disease. The company intends to advance HST-2011 toward clinical development as a potential oral treatment. The latest findings strengthen the scientific rationale for further investigation, but human clinical trials will be necessary to determine whether HST-2011 is safe and effective.
Source: HotSpot Therapeutics press release
